Kyoto Semiconductor Announces Two UV Sensors for Deep UV Sensing Applications
7.2.2023 04:30:00 EET | Business Wire | Press release
Kyoto Semiconductor Co., Ltd. (President and CEO Yoshihisa Shinya, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced two products of GaN*1 UV sensor; "KPDU086SU27-H11Q and KPDU086SU31-H11Q".
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005014/en/
Kyoto Semiconductor KPDU086SU27/KPDU086SU31 (Photo: Business Wire)
The UV sensors "KPDU086SU27-H11Q" and "KPDU086SU31-H11Q" were developed with the aim of achieving higher sensitivity than conventional Si*2 type UV sensors to meet the needs of the deep UV*3 sensing market.
Since conventional Si-type UV sensors detect a wide range of wavelengths, it is common to apply a filter to limit the sensitivity to the UV wavelength range. The amount of light was attenuated by passing through the filter.
The newly developed KPDU086SU27-H11Q and KPDU086SU31-H11Q use GaN to enable direct light reception at the light receiving part of the sensor without using a filter as GaN has sensitivity to a specific wavelength range of ultraviolet light. It is now possible to obtain approximately three times as high sensitivity as Si-type UV sensors. *4
In addition, the products have sensitivity in the wavelength range limited to UV-B*5 and UV-C*6, which are in high demand among ultraviolet rays.
The new products can be used to monitor the ultraviolet light intensity of germicidal lamps in food factories, medical institutions, and water purification-related institutions, and to monitor the light intensity of ozone detection light sources.
The mass production of the GaN UV sensors "KPDU086SU27-H11Q and KPDU086SU31-H11Q" are scheduled to start on April 28, 2023.
For more information
https://www.kyosemi.co.jp/en/products/kpdu086su27-h11q/
https://www.kyosemi.co.jp/en/products/kpdu086su31-h11q/
*1 GaN: Gallium nitride a type of semiconductor
*2 Si: Silicon, a type of semiconductor
*3 Deep ultraviolet rays: UV rays in the emission wavelength range of λ = 200-300 nm. UV-B and UV-C are said to be deep UV rays.
*4 Comparison between KPDU086SU27-H11Q and our Si UV sensor KPDU400F-2
https://www.kyosemi.co.jp/products/kpdu400f-2/
*5 UV-B: Ultraviolet rays in the emission wavelength range of λ = 280 to 315 nm. Sensitivity wavelength range of KPDU086SU31-H11Q
*6 UV-C: Ultraviolet rays in the emission wavelength range of λ = 100 to 280 nm. Sensitivity wavelength range of KPDU086SU27-H11Q
About Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.
Company Website: https://www.kyosemi.co.jp/
*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication and subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230204005014/en/
Contact information
Media Relations, Kyoto Semiconductor Co., Ltd.
Email: Media_relation@kyosemi.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom